Table 1.
Age, gender and key immunological response parameters of study cohorts after 3rd vaccination with BNT162b2.
| Neutralization capacity > 70% | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Study cohorts | Number (%) | Females | Males | Median age | Wildtype | B.1.617.2 | B.1.1.529 | Anti-spike IgG | IFN-γ secretion > |
| (range) | SARS-CoV-2 | (Delta) | (Omicron) | OD ratio > 64 (%) | 4x103 mIU/ml (%) | ||||
| Total vaccinees | 186 (100) | 140 (75) | 46 (25) | 63 (20 - 98) | _ | _ | _ | _ | _ |
| COVID-19-naive, age > 62 | 39 (21) | 26 (67) | 13 (33) | 87 (65 - 95) | 95 | 87 | 46 | 38 | 18 |
| COVID-19-convalescent, all ages | 147 (79) | 114 (78) | 33 (22) | 62 (20 – 98) | 99 | 98 | 75 | 63 | 55 |
| COVID-19-convalescent, age ≤ 62 | 73 (39) | 61 (84) | 12 (16) | 50 (20 - 62) | 100 | 100 | 78 | 41 | 62 |
| COVID-19-convalescent, age > 62 | 74 (40) | 53 (71) | 21 (29) | 84 (63 - 98) | 98 | 97 | 73 | 78 | 50 |
186 individuals undergoing booster vaccination against SARS-CoV-2 using the mRNA vaccine BNT162b2 were recruited in long-term care facilities including 56% residents and 44% healthcare professionals. 147 individuals were COVID-19-convalescent. 39 residents, who never had a SARS-CoV-2 infection, served as reference cohort. IFN-γ, interferon gamma; OD, optical density; SARS-CoV-2, severe acute respiratory syndrome-coronavirus 2.